|
Based on the information provided, no conclusions can be made.As reported, patient was diagnosed with post-op complication of hematoma.As reported, the hematoma resolved on its own without any intervention or medication.Medical affairs has assessed the patient¿s postoperative course as being not serious and likely related to the study device.Review of the device history records confirmed the device was manufactured to specification.Hematoma is known inherent risk of the surgery/use of the device and included as possible complication in the adverse reaction section of the ifu.This mdr reports the ae of hematoma.An additional mdr was submitted to report additional ae of migration, malposition, or contraction.Note: this mdr report is related to a retrospective study conducted to proactively gather real-world evidence on the use and safety of the p4hb product family, including galaflex scaffold, galaflex 3d, and galaflex 3dr. all safety events from the study are adjudicated by the bd medical monitor for an independent assessment of severity and relatedness. in an abundance of caution, events for which relatedness cannot be ruled out are processed for mdr reporting.
|
|
Per clinical trial (b)(4): on (b)(6) 2017, patient underwent bilateral revision augmentation mastopexy using a full vertical and horizontal t incision.2 pieces of galaform (galaflex 3dr) were used.Concomitant procedure included liposuction.On (b)(6) 2017, hematoma; breast was reported.No treatment was given or action taken.Resolved without sequelae on (b)(6) 2017.Review by medical affairs identifies the reported hematoma is likely related to the device and not serious.
|